Jalan Group Launches ₹37.89 Cr Open Offer for Shah Foods Amidst Inactivity

An offer price of Rs 62.50 per equity share and a total consideration of ₹37.89 crore highlight the open offer by Mr. Ankit Jalan and Mr. Anuj Jalan for Shah Foods Limited.

Reader Takeaway: Open offer secures change of control for Jalan Group; operational revival and financial health remain key concerns.

What just happened (today’s filing)

Ankit Jalan and Anuj Jalan, along with Persons Acting in Concert (PACs), are making a mandatory open offer to acquire up to 60,61,900 equity shares of Shah Foods Limited. This represents 26.00% of the company's emerging equity and voting share capital.

The offer price is set at Rs 62.50 per equity share, with the total consideration approximating ₹37.89 crore. The offer period will commence on April 10, 2026, and conclude on April 24, 2026.

Why this matters

This open offer signifies a significant change in control for Shah Foods Limited. Upon successful completion, the acquirers and their PACs are projected to hold approximately 95.39% of the company's emerging equity and voting capital, fundamentally altering its ownership structure.

The backstory (grounded)

Shah Foods Limited, incorporated in 1982, was previously involved in biscuit manufacturing and food processing, with its factory closing on June 30, 2019, leading to no business transactions thereafter. The current open offer is triggered by two primary transactions approved on February 10, 2026.

These include a preferential allotment of 2,27,17,500 equity shares at ₹62.50 per share, partly in exchange for acquiring shares in Tandhan Power Technologies Private Limited. Additionally, a Share Purchase Agreement (SPA) involves acquiring 2,92,839 existing equity shares from current promoters at ₹60 per share.

What changes now

• The Jalan brothers and their associates will become the new promoter group, holding a dominant stake in Shah Foods.
• Existing promoters will be reclassified as public category shareholders.
• The company, currently reporting no business activity and nil revenue, could see a revival under new management, though no specific business plan has been detailed.
• The preferential allotment requires shareholder approval at an EGM scheduled for March 6, 2026.

Risks to watch

• Execution Risks: Potential oversubscription may lead to proportionate acceptance of tendered shares.
• Regulatory Hurdles: Delays in statutory or regulatory approvals, or any litigation leading to a 'stay' of the offer, could postpone the process and payment.
• Financial Penalties: If approvals are delayed, acquirers might incur interest payments on accepted shares.
• Financial Distress: The company faces severe financial distress, with a persistent negative net worth (₹(67.20) Crores as of December 31, 2025) and highly erratic revenue figures, including zero revenue for recent periods.
• Operational Instability: Past operational performance shows extreme volatility, raising questions about the sustainability of any future business model.

Peer comparison

While Shah Foods was historically in the food processing and biscuit manufacturing sector, competing with players like Britannia Industries, Dabur India, and Godrej Consumer Products, its current inactive status means direct operational peers are absent. The focus is on the change of control dynamics rather than ongoing business operations.

Context metrics (time-bound)

• The open offer is priced at Rs 62.50 per equity share, for up to 60,61,900 shares, representing 26.00% of emerging equity, with a total consideration of ₹37.89 crore.
• The offer period is set from April 10, 2026, to April 24, 2026.
• Post-offer, acquirers and PACs are expected to hold approximately 95.39% of the emerging equity and voting share capital.

What to track next

• Shareholder approval for the preferential allotment at the upcoming EGM.
• The successful conclusion of the open offer period from April 10-24, 2026.
• Any future announcements regarding the business strategy or revival plans for Shah Foods Limited under the new management.
• Regulatory approvals required for the transaction.
• The company's financial performance and balance sheet health post-acquisition.